Anti-CD19 Chimeric Antigen Receptor
Showing 1 - 25 of >10,000
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto
Not yet recruiting
- Multiple Sclerosis
- +2 more
- KYV-101 anti-CD19 CAR-T cell therapy
- Standard lymphodepletion regimen
-
Palo Alto, CaliforniaStanford Multiple Sclerosis Center
Nov 13, 2023
Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,
Recruiting
- Lupus Nephritis
- +2 more
- KYV-101 anti-CD19 CAR-T cell therapy
- Standard lymphodepletion regimen
-
Denver, Colorado
- +1 more
Jul 7, 2023
Follicular Lymphoma Trial (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine phosphate)
Not yet recruiting
- Follicular Lymphoma
- Axicabtagene Ciloleucel
- +5 more
- (no location specified)
Sep 21, 2023
Systemic Lupus Erythematosus (SLE) Trial in Shanghai (anti-CD19 CAR NK cells (KN5501))
Recruiting
- Systemic Lupus Erythematosus (SLE)
- anti-CD19 CAR NK cells (KN5501)
-
Shanghai, ChinaChanghai Hospital
Aug 25, 2023
Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis Trial (KYV-101, Cyclophosphamide,
Not yet recruiting
- Idiopathic Inflammatory Myopathies
- +3 more
- KYV-101
- +2 more
- (no location specified)
Nov 21, 2023
Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma Trial (PACE CART19)
Withdrawn
- Acute Lymphoblastic Leukemia
- +2 more
- PACE CART19
- (no location specified)
Mar 9, 2022
Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma Trial in San Francisco (Fludarabine, Cyclophosphamide,
Recruiting
- Refractory Non-Hodgkin Lymphoma
- +8 more
- Fludarabine
- +2 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
May 2, 2022
Multiple Myeloma Trial in Philadelphia (CART-19 cells)
Terminated
- Multiple Myeloma
- CART-19 cells
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Jan 4, 2023
B-cell Non Hodgkin Lymphoma Trial in Seoul (AT101(Anti-CD19 Chimeric Antigen Receptor T cell))
Recruiting
- B-cell Non Hodgkin Lymphoma
- AT101(Anti-CD19 Chimeric Antigen Receptor T cell)
-
Seoul, Korea, Republic ofAsan Medical Center
May 24, 2022
B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)
Active, not recruiting
- B-cell Lymphoma
- PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, Zhejiang University School of Med
Sep 28, 2022
Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- Anti-CD19 and anti-CD20 bicistronic CAR T- cells
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Apr 10, 2023
CD19-ALL, CD19-LNH Trial in Roma (CD19-CAR T cell)
Active, not recruiting
- CD19-ALL
- CD19-LNH
- CD19-CAR T cell
-
Roma, ItalyOspedale Pediatrico Bambino Gesù
Mar 9, 2022
B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,
Recruiting
- B-Cell Non-Hodgkin Lymphoma
- +7 more
- Acalabrutinib
- Axicabtagene Ciloleucel
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 9, 2022
Chemo Resistant Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in Philadelphia (CART22-65s cells,
Active, not recruiting
- Chemotherapy Resistant Acute Lymphoblastic Leukemia
- Refractory Acute Lymphoblastic Leukemia
- CART22-65s cells
- huCART19 Cells
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania
Feb 18, 2022
Lymphoblastic Leukemia, Lymphoblastic Leukemia in Children, Lymphoblastic Leukemia, Acute Adult Trial in Singapore (Anti-CD19
Recruiting
- Lymphoblastic Leukemia
- +5 more
- Anti-CD19 CAR T-cells
-
Singapore, Singapore
- +1 more
Dec 4, 2022
SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma Trial in Taiyuan (CD19 targeted CAR-T cells)
Recruiting
- SLE (Systemic Lupus)
- +4 more
- CD19 targeted CAR-T cells
-
Taiyuan, Shanxi, ChinaShanxi Bethune Hospital
Sep 25, 2023
Acute Lymphoblastic Leukemia (ALL), Non Hodgkin Lymphoma (NHL) Trial in Zhengzhou, Hangzhou (CD19-UCART)
Recruiting
- Acute Lymphoblastic Leukemia (ALL)
- Non Hodgkin Lymphoma (NHL)
- CD19-UCART
-
Zhengzhou, Henan, China
- +1 more
Apr 2, 2022
Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia in Children Trial in Singapore (Phase
Recruiting
- Lymphoblastic Leukemia
- +4 more
- Phase I
- Phase II
-
Singapore, SingaporeKK Women's and Children's hospital
Jun 20, 2022
Primary Mediastinal B-cell Lymphoma, Diffuse, Large B-cell Lymphoma, DLBCL Transformed From Follicular Lymphoma Trial run by the
Completed
- Primary Mediastinal B-cell Lymphoma
- +3 more
- Fludarabine
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 29, 2021
Systemic Lupus Erythematosus (SLE) Trial (BRL-301)
Not yet recruiting
- Systemic Lupus Erythematosus (SLE)
- BRL-301
- (no location specified)
Aug 13, 2023
Relapsed Non Hodgkin Lymphoma, Relapsed Adult ALL, Relapsed Pediatric ALL Trial in Calgary, Edmonton (autologous CD19-directed
Recruiting
- Relapsed Non Hodgkin Lymphoma
- +2 more
- autologous CD19-directed chimeric antigen receptor (CAR) T-cells
-
Calgary, Alberta, Canada
- +5 more
Jul 18, 2022
Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Lymphoma Trial in Dongguan (Drugs and Anti-CD19-CAR transduced T
Completed
- Acute Lymphocytic Leukemia
- +2 more
- Drugs and Anti-CD19-CAR transduced T cells
-
Dongguan, Guangdong, ChinaDepartment of Hematology, Dongguan People's Hospital
Mar 16, 2021
Acute Lymphoblastic Leukemia Trial in Sanhe (CAR-NK-CD19 Cells)
Completed
- Acute Lymphoblastic Leukemia
- CAR-NK-CD19 Cells
-
Sanhe, Hebei, ChinaHebei Yanda Ludaopei Hospital
Nov 24, 2022
Chronic GVHD, Hematologic and Lymphocytic Disorder, Steroid Refractory GVHD Trial in Duarte (procedure, biological, other)
Not yet recruiting
- Chronic Graft Versus Host Disease
- +2 more
- Biopsy
- +11 more
-
Duarte, CaliforniaCity of Hope Medical Center
Aug 7, 2023
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma Refractory, Non-Hodgkin's Lymphoma, Relapsed
Recruiting
- Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- +2 more
- Autologous CAR19 T lymphocytes
-
Prague, CzechiaInstitute of Hematology and Blood Transfusion, Czech Republic
Aug 3, 2022